Long-term Efficacy, Safety and Tolerability of LNP023 in C3G

C3 Glomerulopathy Clinical Trial

Official title:

An Open-label, Non-randomized Extension Study to Evaluate the Long-term Efficacy, Safety and Tolerability of LNP023 in Subjects With C3 Glomerulopathy

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03955445
• Other study ID #: CLNP023B12001B
• Secondary ID: 2018-004253-24
• Status: Recruiting
• Phase: Phase 3
• Start date: October 3, 2019
• Est. completion date: December 1, 2028

Study information

• Verified date: January 2024
• Source: Novartis
• Contact: Novartis Pharmaceuticals
• Phone: 1-888-669-6682
• Email: novartis.email[@]novartis.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy

Description:

The purpose of this extension study is to collect long-term efficacy, safety and tolerability data in eligible participants receiving open-label iptacopan after completing treatment in the C3 glomerulopathy (C3G) Phase II study CLNP023X2202 or the C3G Phase III study CLNP023B12301. Efficacy and safety assessments at the 9 month visit of this extension study in combination with data from CLNP023X2202 (baseline plus 3 months of treatment) afforded the opportunity to evaluate the effects of iptacopan on potential endpoint(s) for the Phase III trial in C3G at 12 months of treatment. In addition, the enrollment of participants from study CLNP023B12301 permits longer-term evaluation of the persistence of effects observed after 6 months (CLNP023B12301 patients randomised to placebo arm) or 12 months (CLNP023B12301 patients randomised to iptacopan arm) of iptacopan treatment. These longer term efficacy assessments may be compared to historical/concurrent control data available from relevant real world databases in C3G patients and used as supportive information for registration purposes. The extension study is expected to continue until the drug product becomes commercially available and accessible (anticipated to be up to approximately 66 months), or the benefit-risk profile is no longer positive, or the program is discontinued for business or strategic reasons. Study CLNP023X2202 has enrolled C3G patients with native kidney disease (Cohort A) and C3G patients who have undergone kidney transplant and have recurrence of C3G (Cohort B); CLNP023B12301 will only enroll patients with native kidneys. "Baseline" refers to the Day 1 visit (pre-dose) of CLNP023X2202 or CLNP023B12301, whereas the Day 1 visit for this C3G extension study (CLNP023B12001B) is identified as "Extension Day 1".

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 94
• Est. completion date: December 1, 2028
• Est. primary completion date: October 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients must have completed the treatment period of the CLNP023X2202 or CLNP023B12301 trial on study drug

Exclusion Criteria:

• Severe concurrent co-morbidities, e.g. advanced cardiac disease (NYHA class IV), severe pulmonary arterial hypertension (WHO class IV), or any illness or medical condition that in the opinion of the investigator and sponsor is likely to prevent the patient from safely tolerating LNP023 or complying with the requirements of the study
• Participants with an active systemic bacterial, viral or fungal infection within 14 days prior to screening, or the presence of fever = 38oC (100.4oF) within 7 days prior to screening.
• History or current diagnosis of ECG abnormalities indicating significant risk of safety for subjects
• History of HIV or any other immunodeficiency disease

Related Conditions & MeSH terms

• C3 Glomerulopathy

Intervention

Drug:
• LNP023
LNP023 capsules

Locations

Country	Name	City	State
Argentina	Novartis Investigative Site	Buenos Aires
Brazil	Novartis Investigative Site	São Paulo	SP
China	Novartis Investigative Site	Beijing
China	Novartis Investigative Site	Shanghai
France	Novartis Investigative Site	Montpellier
France	Novartis Investigative Site	Paris
Germany	Novartis Investigative Site	Erlangen
Germany	Novartis Investigative Site	Essen
Greece	Novartis Investigative Site	Heraklion Crete
Israel	Novartis Investigative Site	Petach Tikva
Israel	Novartis Investigative Site	Petach-Tikva
Italy	Novartis Investigative Site	Ranica	BG
Italy	Novartis Investigative Site	Roma	RM
Japan	Novartis Investigative Site	Asahikawa-city	Hokkaido
Japan	Novartis Investigative Site	Nagoya	Aichi
Japan	Novartis Investigative Site	Sapporo	Hokkaido
Netherlands	Novartis Investigative Site	Leiden	Zuid-Holland
Spain	Novartis Investigative Site	Barcelona	Catalunya
Spain	Novartis Investigative Site	Madrid
Switzerland	Novartis Investigative Site	Bern
Turkey	Novartis Investigative Site	Ankara
United Kingdom	Novartis Investigative Site	London
United Kingdom	Novartis Investigative Site	Newcastle Upon Tyne
United States	Novartis Investigative Site	Iowa City	Iowa
United States	Novartis Investigative Site	Lawrenceville	Georgia
United States	Novartis Investigative Site	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Argentina,  Brazil,  China,  France,  Germany,  Greece,  Israel,  Italy,  Japan,  Netherlands,  Spain,  Switzerland,  Turkey,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CLNP023X2202 Cohort A-native C3G: Number of participants who achieve the composite renal endpoint	A participant meets the requirements of the composite renal endpoint if they satisfy the following criteria at the 9-month visit in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR and (3) either a =50% increase in C3 compared to baseline or an increase to =90 mg/dL (i.e., = the lower limit of normal (LLN)). Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as not meeting the endpoint.	9-month visit
Primary	CLNP023X2202 Cohort B - kidney transplant and recurrent C3G: Change from baseline in the C3 Deposit Score	Change from baseline in the C3 Deposit Score (based on immunofluorescence microscopy) compared to baseline in the CLNP023X2202 study.	6 - to 9- month visit
Primary	Number of AEs of special interest	Number of participants with AEs of special interest will be collected to evaluate the long-term safety and tolerability of iptacopan in participants with C3G	Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301
Primary	Number of participants with study drug discontinuation due to an AE (or any safety issue)	Number of participants with study drug discontinuation due to an AE to evaluate the long-term safety and tolerability of iptacopan in participants with C3G	Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301
Primary	Number of participants with abnormal clinically significant vital signs,ECGs, and safety laboratory measurements	Number of participants with abnormal clinically significant vital signs, ECGs, and safety laboratory measurements to evaluate the long-term safety and tolerability of iptacopan in participants with C3G	Up to 66 months for participants from CLNP023X2202 and up to 36 months for participants from CLNP023B12301
Secondary	CLNP023X2202: Number of participants who achieve the 2-component composite renal endpoint	A participant is defined as achieving the composite renal endpoint if they meet the following criteria at the 9-month visit in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR.; Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as a not meeting the composite renal endpoint.	9-month visit
Secondary	CLNP023X2202: Change from baseline in log-transformed urine protein/creatinine ratio (UPCR)	Long-term effect of LNP023 on renal function in C3G subjects by assessing the change from baseline in log-transformed urine protein/creatinine ratio (UPCR)	3 month visit, 9-month visit and up to 66 months
Secondary	CLNP023X2202: Change from baseline in log-transformed urine albumin/creatinine ratio (UACR)	Long-term effect of LNP023 on renal function in C3G subjects by assessing the change from baseline in log-transformed urine albumin/creatinine ratio (UACR)	3 month visit, 9-month visit and up to 66 months
Secondary	CLNP023X2202: Change from baseline in serum creatinine concentration	Long-term effect of LNP023 on renal function in C3G subjects by assessing the change in serum creatinine at 9 months visit compared to CLNP023X2202 baseline	9-month visit and up to 66 months
Secondary	CLNP023X2202: Change from baseline in estimated glomerular filtration rate (eGFR)	Long-term effect of LNP023 on renal function in C3G subjects by assessing the change in eGFR at 9 months visit compared to CLNP023X2202 baseline	9-month visit and up to 66 months
Secondary	CLNP023X2202: Status of C3G disease progression	Describe the status of C3G disease progression based on glomerular histopathology in a renal biopsy at 6 to 9 months from entry to the study compared to those obtained prior to treatment in the CLNP023X2202 study	6 to 9 month visit
Secondary	CLNP023X2202: Log-transformed ratio to baseline in serum C3	Long-term effect of LNP023 on son C3 at the 9-month visit by evaluating the Log-transformed ratio to baseline in serum C3	9-month visit and up to 66 months
Secondary	CLNP023X2202: Number of participants who achieve the composite renal endpoint	A participant is defined as achieving the composite renal endpoint if they meet the following criteria at times >9 months in CLNP023B12001B: (1) a stable or improved eGFR compared to the baseline visit in CLNP023X2202 (=10% reduction in eGFR), and (2) either =50% reduction compared to the baseline visit in CLNP023X2202 or a reduction to <300 mg/g in UPCR and (3) either a =50% increase in C3 compared to baseline or an increase to =90 mg/dL (i.e., LLN). Initiation of treatment with eculizumab or any other complement pathway modifying agent automatically designates the participant as a not meeting the composite renal endpoint.	Up to 66 months
Secondary	CLNP023X2202: Plasma LNP023 concentration up to 12 months at trough	Measurement of LNP023 plasma concentration to evaluate the pharmacokinetics of iptacopan in participants with prolonged treatment	3-months, 6-months, 9-months and 12-months visits
Secondary	CLNP023B12301: Change from baseline in log-transformed UPCR over time by treatment groups	Change from baseline in log-transformed UPCR will be assessed to evaluate the long-term effect of iptacopan on proteinuria	Up to 36 months
Secondary	CLNP023B12301: Change from Day 180 in log-transformed UPCR over time (placebo arm of study CLNP023B12301)	Change from Day 180 in study CLNP023B12301 in log transformed UPCR will be assessed to evaluate the long-term effect of iptacopan on proteinuria	Up to 36 months
Secondary	CLNP023B12301: Change from baseline in eGFR over time	Change from baseline in eGFR will be assessed to evaluate the long-term effect of iptacopan on eGFR	Up to 36 months
Secondary	CLNP023B12301: Change from Day 180 in study CLNP023B12301 in eGFR over time (placebo arm of study CLNP023B12301)	Change in eGFR over time will be assessed to evaluate the long-term effect of iptacopan on eGFR	Up to 36 months
Secondary	CLNP023B12301: Number of participants who achieve a 2-component composite renal endpoint	A participant is defined as meeting the requirements of the composite renal endpoint if they satisfy the eGFR (a stable or improved eGFR, i.e., =15% reduction in eGFR compared to the baseline visit) and UPCR (=50% reduction in UPCR compared to the baseline visit) criteria assessed at a visit. The rate will be evaluated over time.	Up to 36 months